XJPX4591
Market cap18mUSD
Dec 30, Last price
83.00JPY
1D
2.47%
1Q
2.47%
Jan 2017
-88.21%
IPO
-95.53%
Name
Ribomic Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-20.47%
Revenues
0k
-100.00%
Net income
-1.02b
L-38.04%
CFO
-933m
L-45.41%
Profile
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 65,969 -18.47% | 80,909 -12.02% | |||
Cost of revenue | 1,126,695 | 1,964,010 | 1,943,020 | ||
Unusual Expense (Income) | |||||
NOPBT | (1,126,695) | (1,898,041) | (1,862,111) | ||
NOPBT Margin | |||||
Operating Taxes | 1,210 | 1,210 | 1,210 | ||
Tax Rate | |||||
NOPAT | (1,127,905) | (1,899,251) | (1,863,321) | ||
Net income | (1,024,237) -38.04% | (1,653,002) -1.88% | (1,684,754) 41.91% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 27,121 | 1,332,450 | 354,721 | ||
BB yield | -0.82% | -22.78% | -6.01% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 1,000 | ||||
Net debt | (2,122,295) | (2,847,734) | (2,924,348) | ||
| Cash flow | |||||
Cash from operating activities | (932,757) | (1,708,626) | (1,499,224) | ||
CAPEX | (22,727) | (23,930) | (10,443) | ||
Cash from investing activities | 177,272 | 276,353 | 689,556 | ||
Cash from financing activities | 27,649 | 1,333,771 | 354,721 | ||
FCF | (1,098,688) | (1,916,560) | (1,736,357) | ||
| Balance | |||||
Cash | 3,399,743 | 4,325,182 | 4,701,796 | ||
Long term investments | (1,277,448) | (1,477,448) | (1,777,448) | ||
Excess cash | 2,122,295 | 2,844,436 | 2,920,303 | ||
Stockholders' equity | (956,589) | (930,962) | (1,445,787) | ||
Invested Capital | 4,348,036 | 5,282,408 | 6,105,039 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 35,692 | 31,109 | 28,103 | ||
Price | 93.00 -50.53% | 188.00 -10.48% | 210.00 -42.31% | ||
Market cap | 3,319,318 -43.25% | 5,848,553 -0.90% | 5,901,562 -36.95% | ||
EV | 1,197,023 | 3,000,819 | 2,977,214 | ||
EBITDA | (1,116,193) | (1,897,561) | (1,846,603) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||